Regencell Bioscience
35 hedge funds and large institutions have $8.56M invested in Regencell Bioscience in 2026 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 12 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
13% more funds holding
Funds holding: 31 → 35 (+4)
0.15% more ownership
Funds ownership: 0.13% → 0.28% (+0.15%)
48% less capital invested
Capital invested by funds: $16.5M → $8.56M (-$7.9M)
75% less call options, than puts
Call options by funds: $288K | Put options by funds: $1.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$10M |
| 2 |
Legal & General Group
London,
United Kingdom
|
+$2.84M |
| 3 |
Jane Street
New York
|
+$2.36M |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$1.44M |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
-$804K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$803K |
| 3 |
VA
Vident Advisory
Alpharetta,
Georgia
|
-$442K |
| 4 |
Morgan Stanley
New York
|
-$361K |
| 5 |
State Street
Boston,
Massachusetts
|
-$301K |
RGC Hedge Fund Activity: Q2 2026 in Review
35 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q2 2026, worth a combined $8.56M — down 48% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RGC positions and 12 closed out — a net gain of 4 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $10M. The largest seller was Marex Group, exiting entirely with an estimated $804K sold.
- 35 institutional investors held Regencell Bioscience (RGC) as of Q2 2026, up from 31 in Q1 2026.
- Funds reported $8.56M of Regencell Bioscience stock for Q2 2026, down 48% quarter-over-quarter.
- 16 funds opened new Regencell Bioscience positions in Q2 2026 and 12 closed out, a net change of +4 holders.
- The largest Regencell Bioscience buyer in Q2 2026 was Alyeska Investment Group, an estimated $10M added.
- The largest Regencell Bioscience seller in Q2 2026 was Marex Group, an estimated $804K sold.
Based on aggregated 13F filings for Q2 2026.